Human monoclonal antibody specific for the F protein of respiratory syncytial virus (RSV)

Inventors

Koch, Holger • Urwyler, Simon • Rudolf, Michael P. • Truong, Vu L.

Assignees

Aridis Pharmaceuticals Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-9340604-B1

Patent

Publication Date

2016-05-17

Expiration Date


Abstract

This invention is directed to an antibody construct or fragment thereof derived from an RSV-infected human, such that the antibody construct binds with specificity to RSV fusion protein antigenic region II/A with an affinity of greater than 1×10−9 M. Preferably, the antibody construct is capable of neutralizing RSV strains, including at least one RSV strain that is resistant to palivizumab. The invention further relates to nucleic acids encoding the antibody construct or portions thereof, and cell lines expressing the antibody. This invention further relates to methods for producing said antibody construct, and to the use of said antibody construct for treating or preventing infection of a patient by RSV having a normal or mutated version of F protein.

Core Innovation

The invention relates to a human antibody construct or antibody fragment, designated AR201, that specifically binds to respiratory syncytial virus (RSV) F protein antigenic region II/A. The antibody construct or antibody fragment includes an antibody heavy chain variable region and an antibody light chain variable region, with defined CDR amino acid sequences, and binds with specificity to RSV F protein antigenic region II/A with an affinity greater than 1×10−29 M.

The antibody construct is described as fully human or human-derived and includes specified CDR amino acid sequences for the heavy chain variable region and light chain variable region. The document further associates the antibody with RSV F protein antigenic region II/A as a prophylactic target despite variability and palivizumab resistance, including reference to the K272N mutation at position 272.

The document states that AR201 demonstrates neutralization of both palivizumab-sensitive and palivizumab-resistant RSV strains, including neutralization performance that is described as greater than palivizumab on reference strains and improved neutralization on at least one clinical isolate. The epitope is described as distinct from palivizumab’s presumed epitope region, based on epitope mapping using cross-inhibition and Asp-N fragments.

Claims Coverage

The independent claims cover three treatment approaches: producing the specific antibody construct with defined cDNA-encoded variable regions, treating an RSV-infected patient, and preventing RSV infection in a patient at risk. Across the independent claims, the core inventive features are the defined human heavy- and light-chain variable regions with specified CDR amino acid sequences and binding specificity to RSV F protein antigenic region II/A with affinity greater than 1×10−29 M.

Defined human heavy- and light-chain variable regions with RSV F antigenic region II/A binding affinity

A human antibody construct or antibody fragment comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region and light chain variable region include specified CDR1, CDR2, and CDR3 amino acid sequences, and wherein the antibody construct or antibody fragment binds with specificity to RSV F protein antigenic region II/A with an affinity greater than 1×10−29 M.

Producing the antibody construct or fragment by expressing cDNA encoding the variable regions

A method of producing an antibody construct or antibody fragment by culturing a cell under conditions in which cDNA sequences are expressed, wherein the cell comprises a first cDNA sequence encoding a heavy chain variable region and a second cDNA sequence encoding a light chain variable region, such that the cell produces a human antibody construct or antibody fragment comprising the heavy chain variable region and the light chain variable region with specified CDR amino acid sequences and binding specificity to RSV F protein antigenic region II/A with an affinity greater than 1×10−29 M.

Treating an RSV-infected patient by administering the defined antibody construct or fragment

A method for treating an RSV infected patient comprising administering a human antibody construct or antibody fragment to the patient, wherein the antibody construct or antibody fragment comprises at least a heavy chain variable region and a light chain variable region with specified CDR amino acid sequences, and wherein the antibody construct or antibody fragment binds with specificity to RSV F protein antigenic region II/A with an affinity greater than 1×10−29 M.

Preventing RSV infection by administering the defined antibody construct or fragment

A method for preventing RSV infection in a patient at risk of infection with RSV comprising administering an antibody construct or antibody fragment to the patient, wherein the antibody construct or antibody fragment comprises at least a heavy chain variable region and a light chain variable region with specified CDR amino acid sequences, and wherein the antibody construct or antibody fragment binds with specificity to RSV F protein antigenic region II/A with an affinity greater than 1×10−29 M.

Across the independent claims, the patent centers on a human antibody construct or antibody fragment with defined heavy- and light-chain CDR amino acid sequences that specifically binds RSV F protein antigenic region II/A with affinity greater than 1×10−29 M, including methods for producing the construct via cDNA expression and methods for treating or preventing RSV infection via administration to patients.

Stated Advantages

Neutralizes palivizumab-sensitive and palivizumab-resistant RSV strains.

Neutralization performance is described as greater than palivizumab on reference strains and improved on at least one clinical isolate.

Targets RSV F protein antigenic region II/A as a prophylactic target despite variability and palivizumab resistance.

Epitope is described as distinct from palivizumab’s presumed epitope region.

Documented Applications

Treating an RSV infected patient by administering the human antibody construct or antibody fragment.

Preventing RSV infection in a patient at risk of infection with RSV by administering the human antibody construct or antibody fragment.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.